FindTrial
Sign In

Evaluate the efficacy of rosastat in the treatment of patients with renal anemia in inflammatory state: a retrospective study

Evaluate the efficacy of rosastat in the treatment of patients with renal anemia in inflammatory state: a retrospective study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065946
Enrollment
Unknown
Registered
2022-11-18
Start date
2022-11-18
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal anemia

Interventions

CRP normal group:Not applicable
Micro inflammatory state group:Not applicable
Obvious inflammatory state group:Not applicable

Sponsors

Zhongda Hospital Affiliated to Southeast University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years, regardless of gender; 2. Diagnosed as renal anemia (120g/L >= Hb >= 40g/L); 3. High sensitive c-reactive protein >= 2 mg/L; 4. CKD history >= 3 months.

Exclusion criteria

Exclusion criteria: 1. Human immunodeficiency virus (HIV) positive, active viral hepatitis; 2. Use other ESA (such as Ibeo) to correct anemia during the use of rosastal; 3. Less than 4 weeks to use Rosasta.

Design outcomes

Primary

MeasureTime frame
hemoglobin;CRP;—

Secondary

MeasureTime frame
ferritin;Transferrin saturation;Erythropoietin;—

Countries

China

Contacts

Public ContactTu Yan

Zhongda Hospital Affiliated to Southeast University

tuyan_luck@hotmail.com+86 13851623070

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026